Huntsman Cancer Institute at the University of Utah | Strategic Alliance Partners

June 26, 2023

Huntsman Cancer Institute at the University of Utah, a pioneering innovator dedicated to developing more effective ways to care for and prevent cancer, announced plans today for a new Huntsman Cancer Institute comprehensive cancer center in Utah County.

June 20, 2023

In a recently published manuscript, Howard Colman, MD, PhD, identified a potential breakthrough in glioblastoma treatment.

May 18, 2023

Huntsman Cancer Institute at the University of Utah, the only place in the region devoted to developing new treatments for cancer, announced the opening of the Kathryn F. Kirk Center for Comprehensive Cancer Care and Women’s Cancers. 

May 04, 2023

Sagar Patel, MD, discusses how the timing of autologous stem cell transplant can affect outcomes in those with myelofibrosis, including the risk of patients developing post-transplant complications.

April 13, 2023

Amandeep Godara, MBBS, discusses important patient factors to consider when deciding between a CAR T-cell therapy vs bispecific antibody in relapsed/refractory multiple myeloma, and the importance of mitigating treatment-related toxicities associated with the administration of bispecific antibodies in this disease setting.

April 04, 2023

Neeraj Agarwal, MD, is now a distinguished member of the Fellows of the American Society of Clinical Oncology.

March 30, 2023

Brian Mitzman, MD, FACS, FCCP, discusses the use of adjuvant atezolizumab following platinum-based chemotherapy in patients with resectable non–small cell lung cancer.

March 28, 2023

TALAPRO-2 demonstrated that using talazoparib in combination with enzalutamide may reduce the risk of disease progression or death by 37%.

March 23, 2023

Brian Mitzman, MD, FACS, FCCP, discusses the emergence of immunotherapy as a treatment option for patients with early-stage non–small cell lung cancer.

March 21, 2023

Amandeep Godara, MBBS, discusses CAR T-cell therapies currently available for patients with multiple myeloma.

March 21, 2023

Varghese, known for his innovative research in perioperative care and mentorship to physician-scientists, will become SUS President in February 2024.

March 20, 2023

Updated data from key trials in non–small cell lung cancer continue to demonstrate the superiority of immunotherapy and targeted therapy regimens for non–small cell lung cancer treatment, but the optimal use of these agents in the adjuvant vs neoadjuvant settings is still contested.

March 17, 2023

Brian Mitzman, MD, FACS, FCCP, discusses findings from the phase 3 CheckMate 816 trial in patients with resectable non–small cell lung cancer.

March 02, 2023

Amandeep Godara, MBBS, discusses the evolving treatment landscape in both early and late relapsed multiple myeloma, updated clinical trial results with CAR T-cell therapy, and key considerations when navigating treatment selection in this disease space.

February 28, 2023

Amandeep Godara, MBBS, expands on the advantages and limitations of teclistamab monotherapy in patients with late-relapsed myeloma, discusses the best use of bispecific antibodies and CAR T-cell therapy in this population, and highlights ongoing efforts to mitigate the impact of treatment-related toxicities and improve accessibility across the paradigm.

February 28, 2023

Experts in hematologic malignancies conclude their discussion by discussing BTK degraders and other targets in the treatment of mantle cell lymphoma.

February 27, 2023

Huntsman Cancer Institute at the University of Utah congratulates three of their newest endowed chairs.

February 21, 2023

A comprehensive look at the role of bispecific antibodies, including glofitamab, in the treatment of mantle cell lymphoma.

February 21, 2023

Bijal D. Shah, MD, and Matthew J. Matasar, MD, discuss how they approach treating patients with MCL who rapidly progress on BTK inhibitors.

February 16, 2023

Talazoparib plus enzalutamide generated a statistically significant and clinically meaningful improvement in radiographic progression-free survival vs placebo plus enzalutamide as first-line treatment for patients with metastatic castration-resistant prostate cancer, irrespective of homologous recombination repair status.